The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Lilly’s stock has gone up by 590% in the past five years, mainly due to its successful new drug launches, particularly Mounjaro and Zepbound, and its solid pipeline potential.

Zepbound has been a major hit, ... Now, it’s worth noting Stock Advisor ’s total average return is 998 % — a market-crushing outperformance compared to 174 % for the S&P 500.